Allscripts Announces Second Quarter 2012 Results
Second Quarter Highlights:
- Bookings(1) of
$194.1 million . This compares with bookings of$244.6 million in the second quarter of 2011 and$194.6 million in the first quarter of 2012. - GAAP revenue of
$370.0 million and non-GAAP revenue of$370.7 million . This compares with GAAP and non-GAAP revenue of$356.8 and$363.5 million , respectively, in the second quarter of 2011. - GAAP gross profit for the three months ended
June 30, 2012 , was$157.5 million . Non-GAAP gross profit was$158.2 million for the three months endedJune 30, 2012 , or 42.7 percent of total non-GAAP revenue. This compares with$174.5 million or 48.0 percent of non-GAAP revenue for the prior year. - GAAP operating income for the three months ended
June 30, 2012 , was$17.7 million . Non-GAAP operating income was$51.0 million for three months endedJune 30, 2012 , or 13.8 percent of total non-GAAP revenue. This compares with$74.5 million or 20.5 percent of non-GAAP revenue for the prior year. - GAAP net income of
$8.0 million and GAAP diluted earnings per share of$0.04 . This compares with$15.9 million and$0.08 , respectively, in the second quarter of 2011. - Non-GAAP net income of
$29.3 million and non-GAAP diluted earnings per share of$0.16 . This compares with$42.5 million and$0.22 , respectively, in the second quarter of 2011. $58.8 million in cash flow from operations. This compares with$52.3 million in the second quarter of 2011.- Repurchased approximately 21 million shares of common stock during the three months ended
June 30, 2012 for approximately$225 million .
Please refer to Table 4 "Condensed Non-GAAP Financial Information" for a complete reconciliation of all GAAP and non-GAAP financial measures discussed in this press release.
"Our second-quarter results were solid and demonstrated improvement in several key business metrics," said
"We are aggressively focused on executing our business plan and delivering on our client commitments. We remain on schedule to release important new solution enhancements during the fourth quarter of 2012. Allscripts remains well positioned in a robust market with a comprehensive portfolio spanning the ambulatory, acute and post-acute care delivery environments."
Stock Repurchase Program and Credit Facilities
In
During the three months ended
Any common stock repurchases may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means. Any repurchase activity will depend on factors such as the Company's working capital needs, cash requirements for investments, debt repayment obligations, the Company's stock price, and economic and market conditions. The Company's stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.
In
During the second quarter of 2012, Allscripts repaid approximately
Updated Annual Guidance, Reflects Revised Share Count
Allscripts has revised its financial guidance for 2012 as detailed below to reflect the impact of a reduction in shares outstanding and increase in borrowings associated with the stock repurchase activity. Please see the footnotes at the end of this release for a reconciliation of GAAP and non-GAAP financial presentations and other information.
2012 Guidance(2)
Non-GAAP Revenue |
$1,480.0 to $1,520.0 million |
Non-GAAP Operating Margin |
16.0 to 17.0 percent |
Effective Tax Rate |
36.5 to 37.0 percent |
Non-GAAP Diluted EPS |
$0.77 to $0.83 (Prior $0.74 to $0.80) |
Diluted Shares |
182.0 million (Prior 194.0) |
Conference Call
Allscripts will conduct a conference call today,
A replay of the call will be available two hours after the conclusion of the call, for a period of two weeks, at http://www.allscripts.com or by calling (855) 859-2056 or (404) 537-3406 - Conference ID #97854516.
Supplemental and non-GAAP financial information is also available at http://investor.allscripts.com.
Footnotes |
(1) Bookings reflect the value of executed contracts for software, hardware, services, remote hosting, |
(2) Allscripts non-GAAP guidance for calendar year 2012 assumes the following adjustments to GAAP revenue, |
About Allscripts
Allscripts (NASDAQ: MDRX) delivers the insights that healthcare providers require to generate world-class outcomes. The company's Electronic Health Record, practice management and other clinical, revenue cycle, connectivity and information solutions create a
Table 1 |
||||
Allscripts Healthcare Solutions, Inc. |
||||
Condensed Consolidated Balance Sheets |
||||
(In millions) |
||||
(Unaudited) |
||||
June 30, |
December 31, |
|||
2012 |
2011 |
|||
ASSETS |
||||
Current assets: |
||||
Cash and cash equivalents |
$120.4 |
$157.8 |
||
Accounts receivable, net |
363.0 |
362.8 |
||
Deferred taxes, net |
40.6 |
40.6 |
||
Inventories |
1.3 |
2.0 |
||
Prepaid expenses and other current assets |
130.1 |
117.4 |
||
Total current assets |
655.4 |
680.6 |
||
Long-term marketable securities |
1.6 |
1.7 |
||
Fixed assets, net |
139.2 |
122.6 |
||
Software development costs, net |
108.8 |
98.4 |
||
Intangible assets, net |
457.8 |
489.8 |
||
Goodwill |
1,039.4 |
1,039.4 |
||
Deferred taxes, net |
5.0 |
5.0 |
||
Other assets |
73.9 |
79.8 |
||
Total assets |
$2,481.1 |
$2,517.3 |
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||
Current liabilities: |
||||
Accounts payable |
$59.1 |
$41.2 |
||
Accrued expenses |
99.8 |
103.4 |
||
Accrued compensation and benefits |
27.5 |
31.8 |
||
Deferred revenue |
308.5 |
288.9 |
||
Current maturities of long-term debt and capital lease obligations |
68.1 |
45.5 |
||
Total current liabilities |
563.0 |
510.8 |
||
Long-term debt |
420.9 |
322.7 |
||
Deferred revenue |
19.7 |
18.9 |
||
Deferred taxes, net |
128.9 |
119.7 |
||
Other liabilities |
67.8 |
68.5 |
||
Total liabilities |
1,200.3 |
1,040.6 |
||
Total stockholders' equity |
1,280.8 |
1,476.7 |
||
Total liabilities and stockholders' equity |
$2,481.1 |
$2,517.3 |
Table 2 |
||||||||
Allscripts Healthcare Solutions, Inc. |
||||||||
Condensed Consolidated Statements of Operations |
||||||||
(In millions, except per-share amounts) |
||||||||
(Unaudited) |
||||||||
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||
2012 |
2011 |
2012 |
2011 |
|||||
Revenue: |
||||||||
System sales |
$46.6 |
$64.9 |
$87.3 |
$119.4 |
||||
Professional services |
67.4 |
58.1 |
138.9 |
113.7 |
||||
Maintenance |
113.9 |
103.2 |
228.7 |
203.6 |
||||
Transaction processing and other |
142.1 |
130.6 |
279.8 |
255.4 |
||||
Total revenue |
370.0 |
356.8 |
734.7 |
692.1 |
||||
Cost of revenue: (a) |
||||||||
System sales |
35.1 |
35.9 |
66.7 |
70.8 |
||||
Professional services |
57.0 |
48.4 |
118.7 |
94.1 |
||||
Maintenance |
36.3 |
35.1 |
72.3 |
68.1 |
||||
Transaction processing and other |
84.1 |
69.6 |
163.8 |
131.5 |
||||
Total cost of revenue |
212.5 |
189.0 |
421.5 |
364.5 |
||||
Gross profit |
157.5 |
167.8 |
313.2 |
327.6 |
||||
Selling, general and administrative expenses |
92.3 |
101.5 |
189.6 |
205.7 |
||||
Research and development |
38.2 |
24.8 |
74.4 |
46.8 |
||||
Amortization of intangible assets |
9.3 |
9.4 |
18.5 |
18.6 |
||||
Income from operations |
17.7 |
32.1 |
30.7 |
56.5 |
||||
Interest expense |
(4.4) |
(5.1) |
(8.2) |
(13.0) |
||||
Interest income and other, net |
0.2 |
0.4 |
0.5 |
0.8 |
||||
Income before income taxes |
13.5 |
27.4 |
23.0 |
44.3 |
||||
Provision for income taxes |
(5.5) |
(11.5) |
(9.2) |
(15.8) |
||||
Net income |
$8.0 |
$15.9 |
$13.8 |
$28.5 |
||||
Earnings per share - basic and diluted |
$0.04 |
$0.08 |
$0.07 |
$0.15 |
||||
Weighted average common shares outstanding: |
||||||||
Basic |
182.1 |
189.6 |
186.4 |
189.5 |
||||
Diluted |
184.6 |
193.2 |
188.4 |
192.8 |
||||
(a) Includes pre-tax amortization of intangibles |
$7.2 |
$7.2 |
$14.4 |
$14.6 |
Table 3 |
||||||||
Allscripts Healthcare Solutions, Inc. |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(In millions) |
||||||||
(Unaudited) |
||||||||
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||
2012 |
2011 |
2012 |
2011 |
|||||
Cash flows from operating activities: |
||||||||
Net income |
$8.0 |
$15.9 |
$13.8 |
$28.5 |
||||
Non-cash adjustments to net income |
52.3 |
52.6 |
98.6 |
92.9 |
||||
Cash impact of changes in operating assets and liabilities |
(1.5) |
(16.2) |
21.0 |
(2.3) |
||||
Net cash provided by operating activities |
58.8 |
52.3 |
133.4 |
119.1 |
||||
Cash flows from investing activities: |
||||||||
Capital expenditures |
(19.3) |
(9.4) |
(38.7) |
(21.2) |
||||
Capitalized software |
(13.6) |
(14.0) |
(26.9) |
(30.3) |
||||
Net (purchases) sales and maturities of marketable securities and other investments |
0.0 |
(8.7) |
0.0 |
(12.8) |
||||
Proceeds received from sale of fixed assets |
0.0 |
20.0 |
0.0 |
20.0 |
||||
Change in restricted cash |
0.0 |
0.0 |
0.0 |
2.2 |
||||
Net cash used in investing activities |
(32.9) |
(12.1) |
(65.6) |
(42.1) |
||||
Cash flows from financing activities: |
||||||||
Proceeds from issuance of common stock |
1.8 |
3.1 |
3.9 |
20.0 |
||||
Excess tax benefits from stock-based compensation |
0.0 |
2.9 |
0.1 |
7.1 |
||||
Taxes paid related to net share settlement of equity awards |
(1.3) |
0.0 |
(3.6) |
0.0 |
||||
Net debt borrowings (payments) and refinancing costs |
144.5 |
(25.8) |
119.7 |
(68.3) |
||||
Repurchase of common stock |
(225.4) |
(50.1) |
(226.0) |
(50.1) |
||||
Net cash used in financing activities |
(80.4) |
(69.9) |
(105.9) |
(91.3) |
||||
Effect of exchange rate changes on cash and cash equivalents |
(0.8) |
0.0 |
0.7 |
0.6 |
||||
Net decrease in cash and cash equivalents |
(55.3) |
(29.7) |
(37.4) |
(13.7) |
||||
Cash and cash equivalents, beginning of period |
175.7 |
145.4 |
157.8 |
129.4 |
||||
Cash and cash equivalents, end of period |
$120.4 |
$115.7 |
$120.4 |
$115.7 |
Table 4 |
|||||||||
Allscripts Healthcare Solutions, Inc. |
|||||||||
Condensed Non-GAAP Financial Information |
|||||||||
(In millions, except per-share amounts) |
|||||||||
(Unaudited) |
|||||||||
Three Months Ended |
Three Months Ended |
Six Months Ended |
Six Months Ended |
||||||
6/30/12 |
6/30/11 |
6/30/12 |
6/30/11 |
||||||
Total revenue, as reported |
$370.0 |
$356.8 |
$734.7 |
$692.1 |
|||||
Deferred revenue adjustment |
0.7 |
6.7 |
1.5 |
17.5 |
|||||
Total non-GAAP revenue |
$370.7 |
$363.5 |
$736.2 |
$709.6 |
|||||
Gross profit, as reported |
$157.5 |
$167.8 |
$313.2 |
$327.6 |
|||||
Deferred revenue adjustment |
0.7 |
6.7 |
1.5 |
17.5 |
|||||
Total non-GAAP gross profit |
$158.2 |
$174.5 |
$314.7 |
$345.1 |
|||||
Operating income, as reported |
$17.7 |
$32.1 |
$30.7 |
56.5 |
|||||
Deferred revenue adjustment |
0.7 |
6.7 |
1.5 |
17.5 |
|||||
Acquisition-related amortization |
16.5 |
16.6 |
32.9 |
33.3 |
|||||
Stock-based compensation expense |
9.9 |
8.9 |
17.6 |
15.9 |
|||||
Transaction-related & non-recurring expenses (a) |
6.2 |
10.2 |
9.2 |
23.3 |
|||||
Total non-GAAP operating income |
$51.0 |
$74.5 |
$91.9 |
$146.5 |
|||||
Net income, as reported |
$8.0 |
$15.9 |
$13.8 |
$28.5 |
|||||
Deferred revenue adjustment |
0.5 |
4.1 |
1.0 |
10.7 |
|||||
Acquisition-related amortization |
10.3 |
10.1 |
20.7 |
20.3 |
|||||
Stock-based compensation expense |
6.2 |
5.4 |
11.1 |
9.7 |
|||||
Transaction-related & non-recurring expenses (a) |
3.9 |
6.2 |
5.8 |
15.4 |
|||||
Tax rate alignment |
0.4 |
0.8 |
0.4 |
(1.5) |
|||||
Non-GAAP net income |
$29.3 |
$42.5 |
$52.8 |
$83.1 |
|||||
Tax Rate |
37% |
39% |
37% |
39% |
|||||
Weighted shares outstanding - diluted |
184.6 |
193.2 |
188.4 |
192.8 |
|||||
Earnings per share - diluted, as reported |
$0.04 |
$0.08 |
$0.07 |
$0.15 |
|||||
Non-GAAP earnings per share - diluted |
$0.16 |
$0.22 |
$0.28 |
$0.43 |
|||||
Note: all adjustments to reconcile GAAP to non-GAAP net income are net of tax |
|||||||||
(a) Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions. Non-recurring expenses in the second quarter of 2012 include certain legal, consulting and other fees incurred in connection with activities that are considered one-time. Transaction-related and non-recurring expenses were $6.2 million, pretax, in the second quarter of 2012. |
Explanation of Non-GAAP Financial Measures
Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this release non-GAAP revenue, gross profit, operating income and net income, including non-GAAP net income on a per share basis, which are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Non-GAAP revenue consists of GAAP revenue as reported and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Non-GAAP gross profit consists of GAAP gross profit as reported and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Non-GAAP operating income consists of GAAP operating income as reported and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes and excludes acquisition-related amortization, stock-based compensation expense, transaction-related and non-recurring expenses. Non-GAAP net income consists of GAAP net income as reported, excludes acquisition-related amortization, stock-based compensation expense and transaction-related and non-recurring expenses, and adds back the acquisition-related deferred revenue, in each case net of any related tax effects. Non-GAAP net income also includes a tax rate alignment adjustment.
Acquisition-Related Deferred Revenue. Acquisition-related deferred revenue adjustment reflects the fair value adjustment to deferred revenues acquired in business combinations. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to the acquiree's software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the acquisition date. Allscripts adds back this deferred revenue for its non-GAAP financial measures because it believes the inclusion of this amount directly correlates to the underlying performance of Allscripts operations.
Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with acquisitions or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP operating income and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation and the related amortization expense will recur in future periods.
Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock awards to employees. Allscripts excludes stock-based compensation expense from non-GAAP operating income and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods and such expense will recur in future periods.
Transaction-Related and Non-Recurring Expenses. Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions. Allscripts excludes transaction-related expenses from non-GAAP operating income and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods. Non-recurring expenses in the second quarter of 2012 include certain legal, consulting and other fees incurred in connection with activities that are considered one-time.
Tax Rate Alignment. Tax adjustment to align the current quarter's effective tax rate to the expected annual effective tax rate.
Management also believes that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis provide useful supplemental information to management and investors regarding the underlying performance of the Company's business operations. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments that we have provided and discussed herein. Management also uses this information internally for forecasting and budgeting as it believes that these measures are indicative of the Company's core operating results. In addition, the Company uses non-GAAP revenue, operating income and/or net income to measure achievement under the Company's stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis are performance measures only, and they do not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.
(Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO)
SOURCE
Investors, Seth Frank, +1-312-506-1213, seth.frank@allscripts.com, Media, Ariana Nikitas, +1-312-506-1236, ariana.nikitas@allscripts.com